计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B411998-100μg |
100μg |
现货 ![]() |
| |
| B411998-1mg |
1mg |
现货 ![]() |
| |
| B411998-5mg |
5mg |
期货 ![]() |
| |
| B411998-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Bevacizumab (anti-VEGF), 血管内皮生长因子 A 抑制剂 |
|---|---|
| 别名 | 贝伐珠单抗 | 贝伐单抗 | 贝伐单抗(抗 VEGF) |
| 英文别名 | Recombinant Bevacizumab Antibody | rhuMab VEGF | Avastin | Anti-Human VEGF | Humanized Antibody | Bevacizumab (Anti-Human VEGF, Humanized Antibody) | Bevacizumab | EC 2.7.10.1 antibody | FLT 1 antibody | FLT antibody | Flt-1 antibody | FLT1 antibody | Fms |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | VEGFA |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 血管内皮生长因子 A 抑制剂 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 26.5 kDa (Light Chain) & 51.7 kDa (Heavy Chain), under reducing conditions; 173.3 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 216974-75-3 |
| 分子类型 | 抗体 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
Bevacizumab (anti-VEGF) (B411998) - ELISA
Immobilized Recombinant Human VEGF Protein (rp155965) at 1 μg/mL can bind Bevacizumab (anti-VEGF) (B411998) with the EC50 of 4.16 ng/mL.
Bevacizumab (anti-VEGF) (B411998) - SEC
The purity of Bevacizumab (anti-VEGF) (B411998) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | B411998 | |
| 分析证书 | B411998 | |
| 分析证书 | B411998 | |
| 分析证书 | B411998 |
¥469.90
¥329.90
¥1,143.92
¥469.90
¥669.90
¥375.92
| 1. Glade-Bender J, Kandel JJ, Yamashiro DJ. (2003) VEGF blocking therapy in the treatment of cancer.. Expert Opin Biol Ther, 3 (2): (263-76). [PMID:12662141] |
| 2. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.. N Engl J Med, 349 (5): (427-34). [PMID:12890841] |
| 3. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. (2016) Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.. Ann Oncol, 27 (1): (114-21). [PMID:26487588] |
| 4. Wenjuan Huang, Liwen Wang, Ruhui Yang, Ronggui Hu, Qinxiang Zheng, Xingjie Zan. (2022) Combined delivery of small molecule and protein drugs as synergistic therapeutics for treating corneal neovascularization by a one-pot coassembly strategy. Materials Today Bio, 17 (100456). [PMID:36281304] [10.1016/j.mtbio.2022.100456] |